These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 263286)

  • 1. [125I]hGH metabolism in acromegaly: effects of chronic treatment with 2-Br-alpha-ergocryptine.
    Maneschi F; Navalesi R; Pilo A; Paci A
    J Clin Endocrinol Metab; 1978 Jul; 47(1):110-8. PubMed ID: 263286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromocriptine does not alter growth hormone (GH) responsiveness to GH-releasing hormone in acromegaly.
    Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Liuzzi A; Chiodini PG
    J Clin Endocrinol Metab; 1986 Mar; 62(3):601-4. PubMed ID: 3080469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment with 2-Br-alpha-ergocryptine in acromegaly.
    Belforte L; Camanni F; Chiodini PG; Liuzzi A; Massara F; Molinatti GM; Müller EE; Silvestrini F
    Acta Endocrinol (Copenh); 1977 Jun; 85(2):235-48. PubMed ID: 405832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stable reduction of plasma growth hormone (hGH) levels during chronic administration of 2-Br-alpha-ergocryptine (CB-154) in acromegalic patients.
    Chiodini PG; Liuzzi A; Botalla L; Oppizzi G; Müller EE; Silvestrini F
    J Clin Endocrinol Metab; 1975 Apr; 40(4):705-8. PubMed ID: 1127079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutical effects of bromocriptine (CB 154) in 10 acromegalic subjects. Study of somatotrophic function and clinical survey (author's transl)].
    Fossati P; Asfour M; Brion-Brevan B; Fourlinnie JC; Cappoen JP; Dalle-Furnari MA; Blacker C
    Ann Endocrinol (Paris); 1977; 38(4):291-301. PubMed ID: 332054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sleep-related growth hormone release following 2-bromo-alpha-ergocriptine treatment in acromegalic patients.
    Chihara K; Kato Y; Abe H; Furumoto M; Maeda K
    J Clin Endocrinol Metab; 1977 Jan; 44(1):78-84. PubMed ID: 576232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal control of growth hormone secretion by opiate systems in acromegalic patients: a study with naloxone and 2-Br-alpha-ergocryptine (CB 154).
    Agnati LF; Benfenati F; Frank G; Capelli M; Bernardi P; Calza L
    Med Biol; 1981 Feb; 59(1):58-63. PubMed ID: 7266088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of long term bromocriptine treatment on glucose intolerance in acromegaly.
    Chiba T; Chihara K; Minamitani N; Goto B; Kadowaki S; Taminato T; Matsukura S; Fujita T
    Horm Metab Res; 1982 Feb; 14(2):57-61. PubMed ID: 7040191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly.
    Fløgstad AK; Halse J; Grass P; Abisch E; Djøseland O; Kutz K; Bodd E; Jervell J
    J Clin Endocrinol Metab; 1994 Aug; 79(2):461-5. PubMed ID: 8045964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in growth hormone (GH) secretion induced by human pancreatic GH releasing hormone-44 in acromegaly: a comparison with thyrotropin-releasing hormone and bromocriptine.
    Chiodini PG; Liuzzi A; Dallabonzana D; Oppizzi G; Verde GG
    J Clin Endocrinol Metab; 1985 Jan; 60(1):48-52. PubMed ID: 3917270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bromocriptine acute effect on insulin, glucagon and growth hormone levels in acromegalic patients.
    Fedele D; Molinari M; Meneghel A; Valerio A; Muggeo M; Tiengo A
    J Endocrinol Invest; 1980; 3(2):149-53. PubMed ID: 6993548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bromocriptine therapy in acromegaly: use in patients resistant to conventional therapy and effect on serum levels of somatomedin C.
    Moses AC; Molitch ME; Sawin CT; Jackson IM; Biller BJ; Furlanetto R; Reichlin S
    J Clin Endocrinol Metab; 1981 Oct; 53(4):752-8. PubMed ID: 6793607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy.
    Hartman ML; Veldhuis JD; Vance ML; Faria AC; Furlanetto RW; Thorner MO
    J Clin Endocrinol Metab; 1990 May; 70(5):1375-84. PubMed ID: 2335577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.
    Oppizzi G; Petroncini MM; Dallabonzana D; Cozzi R; Verde G; Chiodini PG; Liuzzi A
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas.
    Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ
    J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term bromocriptine treatment and somatostatin in acromegaly.
    Gáspár L; László FA
    Endokrinologie; 1980 Oct; 76(2):152-62. PubMed ID: 6108852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.
    Lima GA; Wu Z; Silva CM; Barbosa FR; Dias JS; Schrank Y; Strasburger CJ; Gadelha MR
    Growth Horm IGF Res; 2010 Apr; 20(2):87-92. PubMed ID: 19884028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.
    Lamberts SW; Zweens M; Verschoor L; del Pozo E
    J Clin Endocrinol Metab; 1986 Jul; 63(1):16-9. PubMed ID: 2872225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic clearance and production rates of human growth hormone.
    Taylor AL; Finster JL; Mintz DH
    J Clin Invest; 1969 Dec; 48(12):2349-58. PubMed ID: 5355346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Normalization of the GH response to L-DOPA in acromegalics after treatment with bromocriptine].
    Carmina E; Lanzara P; Lo Coco R; Longo RA; Jannì A
    Arch Sci Med (Torino); 1979; 136(3):421-5. PubMed ID: 549547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.